These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23016758)

  • 41. Efficacy of linezolid versus comparator therapies in Gram-positive infections.
    Wilcox MH
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolving resistance among Gram-positive pathogens.
    Munita JM; Bayer AS; Arias CA
    Clin Infect Dis; 2015 Sep; 61 Suppl 2(Suppl 2):S48-57. PubMed ID: 26316558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
    Sader HS; Streit JM; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2004 Nov; 50(3):201-4. PubMed ID: 15541606
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renaissance of vancomycin: approaches for breaking antibiotic resistance in multidrug-resistant bacteria.
    Mühlberg E; Umstätter F; Kleist C; Domhan C; Mier W; Uhl P
    Can J Microbiol; 2020 Jan; 66(1):11-16. PubMed ID: 31545906
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gram-positive bacterial resistance: future treatment options.
    Bassetti M; Melica G; Di Biagio A; Rosso R; Gatti G; Bassetti D
    Curr Opin Investig Drugs; 2003 Aug; 4(8):944-52. PubMed ID: 14508878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current and emerging serious Gram-positive infections.
    Menichetti F
    Clin Microbiol Infect; 2005 May; 11 Suppl 3():22-8. PubMed ID: 15811021
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.
    Pechère JC; Gootz TD
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):405-12. PubMed ID: 9758283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quinupristin/dalfopristin.
    Blondeau JM; Sanche SE
    Expert Opin Pharmacother; 2002 Sep; 3(9):1341-64. PubMed ID: 12186626
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.
    Pea F; Viale P
    Expert Rev Anti Infect Ther; 2007 Apr; 5(2):255-70. PubMed ID: 17402840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New antimicrobial agents as therapy for resistant gram-positive cocci.
    Lentino JR; Narita M; Yu VL
    Eur J Clin Microbiol Infect Dis; 2008 Jan; 27(1):3-15. PubMed ID: 17899228
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neofiscalin A and fiscalin C are potential novel indole alkaloid alternatives for the treatment of multidrug-resistant Gram-positive bacterial infections.
    Bessa LJ; Buttachon S; Dethoup T; Martins R; Vasconcelos V; Kijjoa A; Martins da Costa P
    FEMS Microbiol Lett; 2016 Aug; 363(15):. PubMed ID: 27268269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resistance in antimicrobial photodynamic inactivation of bacteria.
    Maisch T
    Photochem Photobiol Sci; 2015 Aug; 14(8):1518-26. PubMed ID: 26098395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A D-enantiomer of the antimicrobial peptide GL13K evades antimicrobial resistance in the Gram positive bacteria Enterococcus faecalis and Streptococcus gordonii.
    Hirt H; Hall JW; Larson E; Gorr SU
    PLoS One; 2018; 13(3):e0194900. PubMed ID: 29566082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Daptomycin as a promising antimicrobial agent for the treatment of serious infections caused by resistant gram-positive organisms.
    Tarai B; Das P; Kumar D
    Indian J Med Microbiol; 2014; 32(3):353-4. PubMed ID: 25008844
    [No Abstract]   [Full Text] [Related]  

  • 55. Antimicrobial activity of amphipathic α,α-disubstituted β-amino amide derivatives against ESBL - CARBA producing multi-resistant bacteria; effect of halogenation, lipophilicity and cationic character.
    Paulsen MH; Ausbacher D; Bayer A; Engqvist M; Hansen T; Haug T; Anderssen T; Andersen JH; Sollid JUE; Strøm MB
    Eur J Med Chem; 2019 Dec; 183():111671. PubMed ID: 31536892
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens.
    Severina E; Severin A; Tomasz A
    J Antimicrob Chemother; 1998 Mar; 41(3):341-7. PubMed ID: 9578160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antimicrobial resistance in Europe and its potential impact on empirical therapy.
    Rossolini GM; Mantengoli E
    Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998.
    Fluit AC; Verhoef J; Schmitz FJ;
    Eur J Clin Microbiol Infect Dis; 2001 Sep; 20(9):617-25. PubMed ID: 11714042
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gram-positive bacterial resistance. A challenge for the next millennium.
    Bassetti M; Melica G; Cenderello G; Rosso R; Di Biagio A; Bassetti D
    Panminerva Med; 2002 Sep; 44(3):179-84. PubMed ID: 12094131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.